Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vactosertib - MedPacto

Drug Profile

Vactosertib - MedPacto

Alternative Names: EW-7197; NOV 1301; TEW-7197

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ewha Womans University
  • Developer AstraZeneca; Case Comprehensive Cancer Center; MedPacto; Merck & Co; National OncoVenture; Samsung Medical Center; Yonsei University Health System
  • Class Aniline compounds; Antineoplastics; Fluorine compounds; Imidazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma; Pancreatic cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Fibroma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Colorectal cancer; Myelodysplastic syndromes; Osteosarcoma
  • No development reported Solid tumours

Most Recent Events

  • 09 Dec 2023 Efficacy, pharmacodynamics and adverse events data from a phase I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 08 Dec 2023 MedPacto anticipates IND approval from US FDA for phase IIb/III trial for Colorectal cancer in 2023
  • 08 Dec 2023 MedPacto plans a phase IIb/III trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA and South Korea (PO) in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top